Increase/Decrease in Cash: The total change in cash for the company over the given period.
Kyverna Therapeutics, Inc. (KYTX) had Increase/Decrease in Cash of $-62.46M for the most recently reported fiscal quarter, ending 2025-09-30.
| Income Statement Financials | |
-- |
|
$-36.79M |
|
-- |
|
-- |
|
$38.73M |
|
$-38.73M |
|
$1.94M |
|
$-36.79M |
|
$-36.79M |
|
$-36.79M |
|
$-36.79M |
|
$-36.79M |
|
$-36.79M |
|
$-38.73M |
|
$-38.31M |
|
43.41M |
|
43.41M |
|
$-0.85 |
|
$-0.85 |
|
| Balance Sheet Financials | |
$174.93M |
|
$1.79M |
|
$12.23M |
|
$187.16M |
|
$33.87M |
|
$0.01M |
|
$1.34M |
|
$35.21M |
|
$151.95M |
|
$151.95M |
|
$151.95M |
|
43.79M |
|
| Cash Flow Statement Financials | |
$-120.19M |
|
$57.30M |
|
$0.42M |
|
$97.17M |
|
$34.72M |
|
|
Increase/Decrease in Cash |
$-62.46M |
$7.38M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
5.16 |
|
-- |
|
-- |
|
0.00 |
|
0.00 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-120.12M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-24.21% |
|
-24.21% |
|
-19.66% |
|
-24.21% |
|
$3.47 |
|
$-2.77 |
|
$-2.77 |
|